HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Min-Hsiung Huang Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsieh, C.-C. Articles by Wang, L.-S. Search for Related Content PubMed PubMed Citation Articles by Hsieh, C.-C. Articles by Wang, L.-S.

Ann Thorac Surg 1998;66:1159-1163
© 1998 The Society of Thoracic Surgeons

---

Original articles: general thoracic

Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung

^a Division of Thoracic Surgery, Department of Surgery, Cancer Center, Section of Thoracic Oncology, Chest Department, and Department of Pathology, Veterans General Hospital-Taipei, Taipei, Taiwan, Republic of China
^b National Yang Ming University, Taipei, Taiwan, Republic of China

Accepted for publication May 5, 1998.

Address reprint requests to Dr Wang, Division of Thoracic Surgery, Department of Surgery, Veterans General Hospital-Taipei, No. 201, Sec 2, Shih-Pai Rd, Taipei, Taiwan, ROC
e-mail: (gcliu{at}www.vghtpe.gov.tw)

Abstract

Background. Even with early diagnosis and adequate resection, the 5-year survival rate for stage I lung cancer patients is around 60% to 70%. Overexpression of HER-2/neu protein is associated with poor prognosis in lung cancers. In this study, we evaluated the expression of HER-2/neu in cancer cells of lung and assessed their clinicopathologic and prognostic significance.

Methods. From 1986 to 1995, clinical data on 42 consecutive patients who underwent complete surgical resection for stage I lung adenocarcinoma were collected. Expression of HER-2/neu in paraffin-embedded tumor samples was determined by immunohistochemistry and scored with a semiquantitative method.

Results. Twenty-one of 42 patients were positive for HER-2/neu overexpression in tumor. Compared with patients with low HER-2/neu expression, patients with HER-2/neu overexpression had a significantly higher incidence of early tumor recurrence (p = 0.014). Survival was also significantly better in patients without HER-2/neu overexpression than in those with HER-2/neu overexpression (p = 0.0047). By univariate analysis, HER-2/neu overexpression and poor cell differentiation are two important factors correlated with poor prognosis.

Conclusions. Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor’s aggressiveness. Early tumor recurrence was frequently detected in patients with HER-2/neu overexpression. We recommend an individualized therapeutic strategy based on the level of HER-2/neu oncoprotein in the tumor cells.

This article has been cited by other articles:

				L. Thomas, L. A. Doyle, and M. J. Edelman Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy Chest, July 1, 2005; 128(1): 370 - 381. [Abstract] [Full Text] [PDF]

				R. J. Korst and R. G. Crystal Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification Ann. Thorac. Surg., October 1, 2003; 76(4): 1319 - 1326. [Abstract] [Full Text] [PDF]

				C.-M. Lin, A. F.-Y. Li, L.-H. Wu, Y.-C. Wu, F. C.-F. Lin, and L.-S. Wang Adenoid cystic carcinoma of the trachea and bronchus - a clinicopathologic study with DNA flow cytometric analysis and oncogene expression Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 621 - 625. [Abstract] [Full Text] [PDF]

				G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part I J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr., B. Helfrich, A. F. Soriano, W. A. Franklin, M. Varella-Garcia, F. R. Hirsch, A. Baron, C. Zeng, and D. C. Chan Expression of Her-2/neu in Human Lung Cancer Cell Lines by Immunohistochemistry and Fluorescence in Situ Hybridization and its Relationship to in Vitro Cytotoxicity by Trastuzumab and Chemotherapeutic Agents Clin. Cancer Res., October 1, 2001; 7(10): 3239 - 3250. [Abstract] [Full Text] [PDF]

				D. M. Nguyen, D. Lorang, G. A. Chen, J. H. Stewart IV, E. Tabibi, and D. S. Schrump Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis Ann. Thorac. Surg., August 1, 2001; 72(2): 371 - 379. [Abstract] [Full Text] [PDF]

				N.-Y. Hsu, H.-C. Ho, K.-C. Chow, T.-Y. Lin, C.-S. Shih, L.-S. Wang, and C.-M. Tsai Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker of Non-Small Cell Lung Cancer Cancer Res., March 1, 2001; 61(6): 2727 - 2731. [Abstract] [Full Text]

				D. M. Nguyen, S. Desai, A. Chen, T. S. Weiser, and D. S. Schrump Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin Ann. Thorac. Surg., December 1, 2000; 70(6): 1853 - 1860. [Abstract] [Full Text] [PDF]

				L.-S. Wang, K.-C. Chow, W.-Y. Li, C.-C. Liu, Y.-C. Wu, and M.-H. Huang Clinical Significance of Serum Soluble Interleukin 2 Receptor-{{alpha}} in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1445 - 1451. [Abstract] [Full Text]

				D. M. Nguyen, A. Chen, A. Mixon, D. S. Schrump, and S. J. A. Roth SEQUENCE-DEPENDENT ENHANCEMENT OF PACLITAXEL TOXICITY IN NON-SMALL CELL LUNG CANCER BY 17-ALLYLAMINO 17-DEMETHOXYGELDANAMYCIN J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 908 - 915. [Abstract] [Full Text] [PDF]